98%
921
2 minutes
20
Background: Liver fibrosis poses a significant public health challenge given its elevated incidence and associated mortality rates. Diffusion-Weighted Imaging (DWI) serves as a non-invasive diagnostic tool for supporting the identification of liver fibrosis. Deep learning, as a computer-aided diagnostic technology, can assist in recognizing the stage of liver fibrosis by extracting abstract features from DWI images. However, gathering samples is often challenging, posing a common dilemma in previous research. Moreover, previous studies frequently overlooked the cross-comparison information and latent connections among different DWI parameters. Thus, it is becoming a challenge to identify effective DWI parameters and dig potential features from multiple categories in a dataset with limited samples.
Purpose: A self-defined Multi-view Contrastive Learning Network is developed to automatically classify multi-parameter DWI images and explore synergies between different DWI parameters.
Methods: A Dense-fusion Attention Contrastive Learning Network (DACLN) is designed and used to recognize DWI images. Concretely, a multi-view contrastive learning framework is constructed to train and extract features from raw multi-parameter DWI. Besides, a Dense-fusion module is designed to integrate feature and output predicted labels.
Results: We evaluated the performance of the proposed model on a set of real clinical data and analyzed the interpretability by Grad-CAM and annotation analysis, achieving average scores of 0.8825, 0.8702, 0.8933, 0.8727, and 0.8779 for accuracy, precision, recall, specificity and F-1 score. Of note, the experimental results revealed that IVIM-f, CTRW-β, and MONO-ADC exhibited significant recognition ability and complementarity.
Conclusion: Our method achieves competitive accuracy in liver fibrosis diagnosis using the limited multi-parameter DWI dataset and finds three types of DWI parameters with high sensitivity for diagnosing liver fibrosis, which suggests potential directions for future research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/mp.17130 | DOI Listing |
Liver Int
October 2025
GastroZentrum Hirslanden, Digestive Disease Center, Zürich, Switzerland.
Background And Aims: Cholangiopathies, including primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and post-COVID-19 cholangiopathy (PCC), involve chronic cholangiocyte injury, senescence, epithelial-stromal crosstalk, and progressive fibrosis. However, effective in vitro models to capture these interactions are limited. Here, we present a scaffold-free 3D multilineage spheroid model, composed of hepatocyte-like cells (HepG2), cholangiocytes (H69), and hepatic stellate cells (LX-2), designed to recapitulate early fibrogenic responses driven by senescent cholangiocytes.
View Article and Find Full Text PDFLiver Int
October 2025
Division of Gastroenterology, Acireale Hospital, Azienda Sanitaria Provinciale di Catania, Catania, Italy.
Background And Aims: Gut-liver axis has been implicated in the pathophysiology of cirrhosis due to metabolic dysfunction-associated steatotic liver disease (MASLD), an in vitro model for studying epithelial gut dysfunction in MASLD is lacking. In this study, we aimed to characterise intestinal organoids derived from subjects with MASLD.
Materials And Methods: Intestinal organoids were obtained from duodenal samples of individuals with non-fibrotic MASLD and with MASLD-cirrhosis.
Med J Aust
September 2025
QIMR Berghofer, Brisbane, QLD.
Objective: To determine the cumulative incidence of overall and cause-specific mortality among Queensland residents admitted to hospital with cirrhosis during 2007-22, by cirrhosis aetiology.
Study Design: Retrospective cohort study; analysis of linked Queensland Hospital Admitted Patient Data Collection and Queensland Registry of Births, Deaths and Marriages data.
Setting, Participants: Adult Queensland residents (18 years or older) admitted to Queensland hospitals with cirrhosis during 1 July 2007 - 31 December 2022.
Sci Rep
September 2025
Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong, University, Xi'an, Shaanxi, China.
Intern Med
September 2025
Department of Gastroenterology and Hepatology, Toyota Kosei Hospital, Japan.
Agranulocytosis is an extremely rare but potentially fatal immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). Its management, particularly following combination therapies such as durvalumab/tremelimumab (Dur/Tre) for hepatocellular carcinoma (HCC), is challenging owing to limited data. We herein report a 79-year-old man with HCC who developed severe Dur/Tre-induced agranulocytosis that was refractory to granulocyte colony-stimulating factor, high-dose corticosteroids, and intravenous immunoglobulin.
View Article and Find Full Text PDF